Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

ZYME

Zymeworks BC Inc

Jan 21 • 03:38PM ET

14.29

Dollar change +0.41
Percentage change 2.94	%

Healthcare • Biotechnology • USA • NASD

Peers: AMGN BIIB GILD REGN VRTX INCY ALNY EXEL NBIX IONS

| Held by: VTI IWM IWN IBB BSVO VTWO DFAC VHT DFAS IWC

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-1.51	Insider Own	4.15%	Shs Outstand	69.58M	Perf Week	2.35%
Market Cap	992.30M	Forward P/E	-	EPS next Y	-1.75	Insider Trans	38.21%	Shs Float	66.57M	Perf Month	6.87%
Income	-113.67M	PEG	-	EPS next Q	-0.10	Inst Own	100.90%	Short Float	6.23%	Perf Quarter	6.08%
Sales	62.20M	P/S	15.95	EPS this Y	16.11%	Inst Trans	1.00%	Short Ratio	8.03	Perf Half Y	46.10%
Book/sh	5.23	P/B	2.73	EPS next Y	-21.02%	ROA	-21.79%	Short Interest	4.15M	Perf Year	44.91%
Cash/sh	4.28	P/C	3.34	EPS next 5Y	-	ROE	-28.73%	52W Range	7.97 - 17.70	Perf YTD	-2.40%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-6.52%	ROI	-29.58%	52W High	-19.27%	Beta	1.09
Dividend TTM	-	Quick Ratio	4.10	Sales past 5Y	341.20%	Gross Margin	82.55%	52W Low	79.28%	ATR (14)	0.81
Dividend Ex-Date	-	Current Ratio	4.10	EPS Y/Y TTM	-148.23%	Oper. Margin	-194.58%	RSI (14)	52.46	Volatility	6.50% 6.17%
Employees	277	Debt/Eq	0.06	Sales Y/Y TTM	-86.52%	Profit Margin	-182.75%	Recom	1.50	Target Price	20.44
Option/Short	Yes / Yes	LT Debt/Eq	0.05	EPS Q/Q	3.54%	Payout	-	Rel Volume	0.30	Prev Close	13.88
Sales Surprise	-10.62%	EPS Surprise	1.71%	Sales Q/Q	-3.07%	Earnings	Oct 31 AMC	Avg Volume	516.87K	Price	14.29
SMA20	0.63%	SMA50	-0.94%	SMA200	24.60%	Trades		Volume	148,036	Change	2.94%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-16-24	Upgrade	JP Morgan	Neutral → Overweight	$18
Nov-07-24	Upgrade	Leerink Partners	Market Perform → Outperform	$10 → $25
Nov-01-24	Downgrade	Wells Fargo	Overweight → Equal Weight	$12
Mar-21-23	Resumed	Wells Fargo	Overweight	$12
Jan-04-23	Reiterated	H.C. Wainwright	Neutral	$10 → $8
Dec-20-22	Upgrade	Jefferies	Hold → Buy	$7.70 → $11
Nov-01-22	Downgrade	H.C. Wainwright	Buy → Neutral	$40 → $8
Oct-21-22	Downgrade	SVB Leerink	Outperform → Mkt Perform	$8
Oct-04-22	Resumed	Wells Fargo	Overweight	$45 → $9
May-05-22	Upgrade	Guggenheim	Neutral → Buy	$14
Mar-15-22	Initiated	Evercore ISI	Outperform	$15
Dec-10-21	Upgrade	SVB Leerink	Mkt Perform → Outperform
Nov-17-21	Resumed	Guggenheim	Neutral
Oct-07-21	Initiated	Jefferies	Hold	$32
Mar-31-21	Initiated	Credit Suisse	Outperform	$55
Feb-25-21	Downgrade	SVB Leerink	Outperform → Mkt Perform	$41
Feb-08-21	Resumed	H.C. Wainwright	Buy	$57
Jan-25-21	Downgrade	Citigroup	Buy → Neutral	$50 → $53
Sep-29-20	Resumed	JP Morgan	Neutral	$48
Aug-06-20	Initiated	SVB Leerink	Outperform	$45

Show Previous Ratings

Jan-08-25 04:05PM	Zymeworks Outlines Strategic Priorities and Outlook for 2025 and 2026 (GlobeNewswire) -6.44%
Dec-12-24 08:30AM	Zymeworks Hosts RandD Day Highlighting Continued Clinical Progress in Oncology Programs and Expansion into Autoimmune and Inflammatory Diseases (GlobeNewswire)
08:30AM	Zymeworks Hosts R&D Day Highlighting Continued Clinical Progress in Oncology Programs and Expansion into Autoimmune and Inflammatory Diseases (GlobeNewswire)
Nov-21-24 06:05AM	Zymeworks Announces Participation in Upcoming Investor Conferences (GlobeNewswire) -5.98%
06:00AM	FDA Grants U.S. Approval of Ziihera (zanidatamab-hrii) for the Treatment of Adults with Previously Treated, Unresectable or Metastatic HER2-positive (IHC 3+) Biliary Tract Cancer (BTC) (GlobeNewswire)
06:00AM	Loading…
Nov-05-24 06:00AM	Zymeworks Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating ZW191 in Folate Receptor-? Expressing Advanced Solid Tumors (GlobeNewswire)
Oct-31-24 04:05PM	Zymeworks Provides Corporate Update and Reports Third Quarter 2024 Financial Results (GlobeNewswire)
Oct-30-24 09:14AM	Zymeworks Inc (ZYME) Q3 2024 Earnings Report Preview: What To Look For (GuruFocus.com)
Oct-29-24 06:00AM	Zymeworks Announces Participation in Upcoming Investor Conferences (GlobeNewswire)
Oct-25-24 06:00AM	Zymeworks Presents New Preclinical Data on Antibody-Drug Conjugate Programs at EORTC-NCI-AACR Conference (GlobeNewswire)
Oct-21-24 06:00AM	Zymeworks Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating ZW171 in Advanced Mesothelin-Expressing Cancers (GlobeNewswire)
Oct-10-24 06:30AM	Zymeworks to Report Third Quarter 2024 Financial Results and Host Conference Call on October 31, 2024 (GlobeNewswire)
Sep-19-24 12:08PM	Cancer Research Sees Major Boost as New Breakthroughs Emerge from Key Oncology Players (PR Newswire)
Sep-18-24 06:00AM	Zymeworks to Present Preclinical Data on Antibody-Drug Conjugate Programs at EORTC-NCI-AACR Conference (GlobeNewswire)
Sep-03-24 04:30PM	Zymeworks Reports Inducement Grant Under Nasdaq Stock Market Rule 5635(c) (GlobeNewswire)
06:30AM	Loading…
Aug-22-24 06:30AM	Zymeworks Announces Participation in Upcoming Investor Conferences (GlobeNewswire)
Aug-01-24 04:10PM	Zymeworks Announces Share Repurchase Program of up to $60 Million of its Common Stock (GlobeNewswire)
04:05PM	Zymeworks Provides Corporate Update and Reports Second Quarter 2024 Financial Results (GlobeNewswire)
Jul-30-24 06:30AM	Zymeworks Announces Participation in Upcoming Investor Conferences (GlobeNewswire)
Jul-25-24 04:30PM	Zymeworks Appoints Leone Patterson as Chief Business and Financial Officer (GlobeNewswire)
Jul-22-24 06:00AM	Zymeworks Announces FDA Clearance of Investigational New Drug Application for ZW191, a Novel Folate Receptor- Targeted Topoisomerase I Inhibitor Antibody-Drug Conjugate (GlobeNewswire)
Jul-11-24 06:30AM	Zymeworks To Report Second Quarter 2024 Financial Results and Host Conference Call on August 1, 2024 (GlobeNewswire) +6.82%
Jun-17-24 06:00AM	Zymeworks Announces FDA Clearance of Investigational New Drug Application for ZW171, a novel 2+1 T-cell Targeting Bispecific Antibody for Mesothelin-expressing Cancers (GlobeNewswire) -5.53%
Jun-10-24 06:00AM	Zymeworks Announces China NMPA Acceptance of Biologics License Application for Zanidatamab for Second-Line Treatment of Biliary Tract Cancer (GlobeNewswire)
May-28-24 06:30AM	Zymeworks Announces Participation in Upcoming Investor Conferences (GlobeNewswire)
May-19-24 09:00PM	Bragar Eagel & Squire, P.C. Is Investigating Zymeworks, Regeneron, Jabil, and DoubleVerify and Encourages Investors to Contact the Firm (GlobeNewswire)
May-16-24 04:20PM	Kirby McInerney LLP is Investigating Potential Shareholder Claims Against Zymeworks Inc. (ZYME) (Business Wire)
May-02-24 04:05PM	Zymeworks Provides Corporate Update and Reports First Quarter 2024 Financial Results (GlobeNewswire)
Apr-30-24 06:00AM	Zymeworks Announces Participation in Upcoming Investor Conferences (GlobeNewswire)
Apr-11-24 06:00AM	Zymeworks To Report First Quarter 2024 Financial Results and Host Conference Call on May 2, 2024 (GlobeNewswire)
09:35AM	Loading…
Apr-10-24 09:35AM	Zymeworks (ZYME) Loses -13.41% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks)
Apr-08-24 06:00AM	Zymeworks Presents New Data from Multiple Preclinical Development Programs at 2024 American Association for Cancer Research Annual Meeting (GlobeNewswire)
Mar-28-24 06:00AM	Zymeworks Announces Appointment of Dr. Neil Gallagher to its Board of Directors (GlobeNewswire)
Mar-27-24 06:00AM	Zymeworks Announces Participation in Upcoming Investor Conferences (GlobeNewswire)
Mar-22-24 12:00PM	Zymeworks (ZYME) Upgraded to Buy: What Does It Mean for the Stock? (Zacks)
Mar-11-24 12:44PM	20 Highest Paying Countries for Biotechnology (Insider Monkey)
Mar-09-24 01:09PM	12 Most Undervalued Biotech Stocks To Buy According To Hedge Funds (Insider Monkey)
Mar-07-24 06:39AM	Zymeworks halts plans for phase 2 ADC trial to mull 'evolving clinical landscape' (FierceBiotech.com) -6.46%
Mar-06-24 10:53PM	ZYME Stock Earnings: Zymeworks Beats EPS, Beats Revenue for Q4 2023 (InvestorPlace)
04:09PM	Zymeworks Reports Fourth Quarter and Full Year 2023 Financial Results (GlobeNewswire)
Mar-05-24 04:30PM	Zymeworks to Present Preclinical Data on Antibody-Drug Conjugate and Multispecific Platforms at the American Association for Cancer Research Annual Meeting (GlobeNewswire)
Feb-28-24 10:00AM	Analysts Estimate Zymeworks Inc. (ZYME) to Report a Decline in Earnings: What to Look Out for (Zacks) -6.51%
Feb-27-24 06:00AM	Zymeworks Announces Participation in Upcoming Investor Conferences (GlobeNewswire)
Feb-14-24 06:00AM	Zymeworks To Host Fourth Quarter and Full Year 2023 Results Conference Call (GlobeNewswire)
Feb-09-24 08:00AM	InMed Pharmaceuticals Strengthens Executive Leadership Team with Appointment of Ms. Netta Jagpal as Chief Financial Officer (Newsfile)
Feb-08-24 06:00AM	Zymeworks Announces Appointment of Dr. Alessandra Cesano to its Board of Directors (GlobeNewswire)
Jan-31-24 06:00AM	Zymeworks Announces Participation in Upcoming Investor Conferences (GlobeNewswire)
Jan-11-24 12:00PM	Zymeworks Inc. (ZYME) Is Up 1.64% in One Week: What You Should Know (Zacks)
Jan-04-24 06:15AM	Zymeworks Outlines Strategic Priorities and Outlook for 2024 and 2025 (GlobeNewswire)
06:00AM	Zymeworks Announces Additional Leadership Appointments (GlobeNewswire)
Dec-26-23 08:00AM	Zymeworks Announces $50 Million Private Placement to EcoR1 Capital (GlobeNewswire) +8.65%
Dec-15-23 08:30AM	Zymeworks Added to Nasdaq Biotechnology Index (GlobeNewswire)
Dec-08-23 10:11AM	5 Best Healthcare Stocks For the Long-Term (Insider Monkey)
Nov-30-23 08:30AM	Zymeworks Announces Participation in Upcoming Investor Conference (GlobeNewswire)
Nov-08-23 05:33PM	Zymeworks Inc. (NYSE:ZYME) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-07-23 04:05PM	Zymeworks Provides Corporate Update and Reports Third Quarter 2023 Financial Results (GlobeNewswire)
Nov-01-23 08:30AM	Zymeworks Announces Participation in Upcoming Investor Conferences (GlobeNewswire)
Oct-17-23 08:30AM	Zymeworks To Host Third Quarter 2023 Results Conference Call (GlobeNewswire)
Oct-16-23 04:30PM	Zymeworks Announces New Director Nominee (GlobeNewswire) +8.46%
Aug-10-23 04:05PM	Zymeworks Provides Corporate Update and Reports Second Quarter 2023 Financial Results (GlobeNewswire) -7.60%
Aug-01-23 08:30AM	Zymeworks Announces Participation in Upcoming Investor Conferences (GlobeNewswire)
Jul-19-23 08:30AM	Zymeworks To Host Second Quarter 2023 Results Conference Call (GlobeNewswire)
Jul-03-23 08:30AM	Zymeworks Announces Participation in Upcoming Investor Conference (GlobeNewswire)
Jun-29-23 04:05PM	Zymeworks Appoints New Director (GlobeNewswire)
Jun-26-23 08:30AM	Zymeworks Set to Join Russell 3000®, Russell 2000®, and Russell Microcap® Indexes (GlobeNewswire)
Jun-02-23 06:41PM	Jazz Pharmaceuticals and Zymeworks Present Positive Pivotal Phase 2b Trial Data at ASCO 2023 Evaluating Zanidatamab in HER2-Amplified Biliary Tract Cancers (PR Newswire)
Jun-01-23 08:30AM	Zymeworks Announces Participation in Upcoming Investor Conferences (GlobeNewswire)
May-18-23 08:30AM	Zymeworks Announces Departure of Neil Klompas, President and Chief Operating Officer (GlobeNewswire)
May-08-23 04:05PM	Zymeworks Provides Corporate Update and Reports First Quarter 2023 Financial Results (GlobeNewswire) +12.79%
May-01-23 08:30AM	Zymeworks Announces Participation in Upcoming Investor Conferences (GlobeNewswire)
Apr-18-23 04:05PM	Zymeworks Presents New Data from Multiple Preclinical and Clinical Development Programs at the 2023 American Association for Cancer Research Annual Meeting (GlobeNewswire)
Apr-17-23 08:30AM	Zymeworks To Host First Quarter 2023 Results Conference Call (Business Wire)
Apr-10-23 08:30AM	Zymeworks Announces Appointment of Derek J. Miller to its Board of Directors (Business Wire)
Apr-03-23 08:30AM	Zymeworks Announces Participation in Upcoming Investor Conferences (Business Wire)
Mar-14-23 04:30PM	Zymeworks to Present Updated Data on Multiple Product Candidates at the American Association for Cancer Research (AACR) Annual Meeting (Business Wire)
Mar-07-23 04:05PM	Zymeworks Reports Fourth Quarter and Full Year 2022 Financial Results (Business Wire)
Feb-28-23 08:30AM	Zymeworks Announces Participation in Upcoming Investor Conferences (Business Wire)
Feb-21-23 08:30AM	Zymeworks To Host Fourth Quarter And Full Year 2022 Results Conference Call (Business Wire)
Jan-25-23 08:30AM	Zymeworks Announces Participation in Upcoming Investor Conferences (Business Wire)
Jan-19-23 07:45AM	Jazz Pharmaceuticals and Zymeworks Announce 84% Overall Survival at 18 Months from Phase 2 Trial Evaluating Zanidatamab in HER2-Expressing Metastatic Gastroesophageal Adenocarcinoma (PR Newswire)
Jan-04-23 04:15PM	Zymeworks Provides Corporate Update on Key Strategic Priorities and Outlook for 2023 (Business Wire)
Dec-21-22 07:30AM	Zymeworks Announces Participation in Upcoming Investor Conference (Business Wire) +23.59%
07:30AM	Jazz Pharmaceuticals and Zymeworks Announce Jazz has Confirmed Opt-in and Advances Partnership for Zanidatamab (PR Newswire)
Dec-19-22 07:00AM	Zymeworks Announces Positive Topline Data in the Pivotal HERIZON-BTC-01 Trial of Zanidatamab (Business Wire) +5.11%
Dec-14-22 04:15PM	Zanidatamab Clinical Data Selected For Presentation At The American Society Of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium (Business Wire)
Dec-09-22 08:00AM	New Clinical Data for Zanidatamab in HER2+ /HR+ Metastatic Breast Cancer Presented Today at 2022 SABCS (Business Wire) -5.23%
Dec-05-22 08:30AM	Zymeworks to Transfer Stock Listing to Nasdaq (Business Wire)
Nov-29-22 08:30AM	Zymeworks Announces Expiration of Hart-Scott-Rodino Waiting Period for Zanidatamab License Agreement with Jazz Pharmaceuticals (Business Wire)
Nov-24-22 12:20PM	Why Zymeworks Inc. (ZYME) Might be Well Poised for a Surge (Zacks)
Nov-22-22 09:55AM	Wall Street Analysts Believe Zymeworks Inc. (ZYME) Could Rally 59%: Here's is How to Trade (Zacks)
08:30AM	Zymeworks Announces Participation in Upcoming Investor Conference (Business Wire)
Nov-21-22 12:22PM	Jazz Pharma's (JAZZ) Gets FDA Nod for Rylaze's New Dosing Option (Zacks)
09:55AM	Zymeworks Inc. (ZYME) Just Flashed Golden Cross Signal: Do You Buy? (Zacks)
09:00AM	Zymeworks Announces Abstract For Zanidatamab In Late-Line HER2-Positive Hormone-Receptor Positive (HR+) Metastatic Breast Cancer At The San Antonio Breast Cancer Symposium (SABCS) (Business Wire)
Nov-08-22 05:45PM	Zymeworks Inc. (ZYME) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
04:22PM	Zymeworks Provides Corporate Update and Reports Third Quarter 2022 Financial Results (Business Wire)
Nov-02-22 10:00AM	Mirum Pharmaceuticals, Inc. (MIRM) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release (Zacks) -5.64%
Nov-01-22 10:01AM	Zymeworks Inc. (ZYME) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release (Zacks)
Oct-31-22 04:42PM	Why Shares of Zymeworks Rose 12.18% on Monday (Motley Fool) +11.73%
Oct-21-22 01:35PM	Analyst Moves To Sidelines After Jazz Pharma Deal Shifts Zymeworks To Early Stage Pipeline (Benzinga)

Zymeworks, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel, multifunctional biotherapeutics. Its product includes Zanidatamab, which is a novel bispecific antibody that targets two distinct domains of the human epidermal growth factor receptor 2 (HER2). Zanidatamab's unique binding properties result in multiple mechanisms of action that may enable it to address unmet need in patient populations with HER2-expressing cancers. The company was founded on September 8, 2003 and is headquartered in Middletown, DE.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
EcoR1 Capital, LLC	Director	Jan 13 '25	Buy	13.39	74,125	992,875	15,485,203	Jan 15 06:12 PM
EcoR1 Capital, LLC	Director	Jan 14 '25	Buy	13.56	54,500	739,265	15,539,703	Jan 15 06:12 PM
EcoR1 Capital, LLC	Director	Jan 15 '25	Buy	14.01	39,029	546,671	15,578,732	Jan 15 06:12 PM
EcoR1 Capital, LLC	Director	Jan 10 '25	Buy	13.13	204,098	2,678,990	15,411,078	Jan 10 06:27 PM
EcoR1 Capital, LLC	Director	Jan 08 '25	Buy	14.07	21,021	295,829	15,206,980	Jan 10 06:27 PM
Moore Paul Andrew	Chief Scientific Officer	Jan 06 '25	Option Exercise	0.00	37,166	0	34,741	Jan 06 08:35 PM
Moore Paul Andrew	Chief Scientific Officer	Jan 06 '25	Sale	14.92	21,200	316,391	14,741	Jan 06 08:35 PM
Galbraith Kenneth	Chair & CEO	Jan 06 '25	Option Exercise	0.00	114,332	0	114,209	Jan 06 08:34 PM
Galbraith Kenneth	Chair & CEO	Jan 06 '25	Sale	14.92	57,291	855,017	47,543	Jan 06 08:34 PM
Smith Jeffrey T L	EVP & Chief Medical Officer	Jan 06 '25	Option Exercise	0.00	20,000	0	20,000	Jan 06 08:19 PM
Smith Jeffrey T L	EVP & Chief Medical Officer	Jan 06 '25	Sale	14.92	11,110	165,807	8,890	Jan 06 08:19 PM
Smith Jeffrey T L	Officer	Jan 06 '25	Proposed Sale	14.46	11,110	160,651		Jan 06 07:50 PM
Moore Paul Andrew	Officer	Jan 06 '25	Proposed Sale	14.46	21,200	306,552		Jan 06 07:43 PM
Galbraith, Kenneth	Officer	Jan 06 '25	Proposed Sale	14.46	57,291	828,428		Jan 06 07:37 PM
EcoR1 Capital, LLC	Director	Jan 02 '25	Buy	14.78	157,880	2,333,403	15,185,959	Jan 02 05:51 PM
EcoR1 Capital, LLC	Director	Dec 31 '24	Buy	14.57	146,501	2,134,446	15,028,079	Jan 02 05:51 PM
EcoR1 Capital, LLC	Director	Dec 30 '24	Buy	14.47	58,988	853,326	14,881,578	Jan 02 05:51 PM
EcoR1 Capital, LLC	Director	Dec 27 '24	Buy	14.49	101,659	1,473,181	14,822,590	Dec 27 06:41 PM
EcoR1 Capital, LLC	Director	Dec 26 '24	Buy	14.38	16,692	240,038	14,720,931	Dec 27 06:41 PM
EcoR1 Capital, LLC	Director	Dec 24 '24	Buy	14.12	11,958	168,896	14,704,239	Dec 27 06:41 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ZYME

Zymeworks BC Inc

Upgrade your FINVIZ experience